About Alcresta Therapeutics
Alcresta Therapeutics develops enzyme-based products targeting fat malabsorption in patients with rare diseases who rely on enteral feeding for nutrition. The company focuses on addressing a specific clinical gap: many patients requiring enteral nutrition cannot adequately digest fat, which is essential for growth, immune function, and organ health, with exocrine pancreatic insufficiency a recognised driver of this problem.
Central to its pipeline is RELiZORB, a cartridge-based delivery system containing iLipase, a patented microbead and enzyme technology developed to improve fat digestion directly within the enteral feeding process. The product is designed for use both in hospital settings and by patients receiving enteral feeds at home, reflecting the real-world care environments where fat malabsorption creates the most significant clinical burden.
Alcresta's development work spans pre-clinical and clinical study stages, with published real-world use studies contributing to the growing evidence base for its approach. The company's stated mission centres on enabling patients with serious medical conditions to absorb the nutritional benefits of enteral feeding, reducing the risk of poor outcomes associated with fat malabsorption.
Based in the United States, Alcresta operates with a leadership structure that includes a board of directors, reflecting a governance model typical of a clinical-stage biotechnology firm. Its investor relations function and active careers programme indicate ongoing operations and continued development activity.
Further information is available at alcresta.com.
